ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
AzurRx BioPharma Inc

AzurRx BioPharma Inc (AZRX)

3.45
0.00
(0.00%)
At close: January 06 3:00PM
3.45
0.00
( 0.00% )

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
3.45
Bid
3.41
Ask
3.51
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
3.45
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
13,500,000
Dividend Yield
-
PE Ratio
-2.48
Earnings Per Share (EPS)
-1.19
Revenue
-
Net Profit
-16.1M

About AzurRx BioPharma Inc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
-

AZRX Latest News

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI” Three IBD clinical indications, including ulcerative colitis and Crohn’s disease, added to...

AzurRx BioPharma Announces Reverse Stock Split

BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the...

AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic...

AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned Part 2 of RESERVOIR Trial to Enroll Up to 150 Patients to Evaluate Efficacy of FW-1022...

AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted...

AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)

MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpointsStudy data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary...

AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819

BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted...

AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

AZRX - Frequently Asked Questions (FAQ)

What is the current AzurRx BioPharma share price?
The current share price of AzurRx BioPharma is US$ 3.45
How many AzurRx BioPharma shares are in issue?
AzurRx BioPharma has 13,500,000 shares in issue
What is the market cap of AzurRx BioPharma?
The market capitalisation of AzurRx BioPharma is USD 46.58M
What is the 1 year trading range for AzurRx BioPharma share price?
AzurRx BioPharma has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of AzurRx BioPharma?
The price to earnings ratio of AzurRx BioPharma is -2.48
What is the reporting currency for AzurRx BioPharma?
AzurRx BioPharma reports financial results in USD
What is the latest annual profit for AzurRx BioPharma?
The latest annual profit of AzurRx BioPharma is USD -16.1M
What is the registered address of AzurRx BioPharma?
The registered address for AzurRx BioPharma is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904
What is the AzurRx BioPharma website address?
The website address for AzurRx BioPharma is www.enterothera.com
Which industry sector does AzurRx BioPharma operate in?
AzurRx BioPharma operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MSAIMultiSensor AI Holdings Inc
US$ 2.76
(38.00%)
2.43M
MCVTMill City Ventures III Ltd
US$ 2.899
(28.27%)
45.28k
QRTEBQurate Retail Inc
US$ 3.13
(22.27%)
103
NARIInari Medical Inc
US$ 78.93
(21.43%)
4.69M
XTIAXTI Aerospace Inc
US$ 0.1051
(19.43%)
340.21M
AMSTAmesite Inc
US$ 3.35
(-17.28%)
59.4k
SLRNACELYRIN Inc
US$ 2.93
(-16.05%)
497.96k
GDTCCytoMed Therapeutics Ltd
US$ 2.92
(-14.87%)
60.93k
BOXLBoxlight Corporation
US$ 1.45
(-13.69%)
2.03M
ACXPAcurx Pharmaceuticals Inc
US$ 0.9523
(-12.63%)
146.11k
XTIAXTI Aerospace Inc
US$ 0.1051
(19.43%)
340.21M
SVMHSRIVARU Holding Ltd
US$ 0.051
(10.15%)
28.77M
CRKNCrown Electrokinetics Corporation
US$ 0.1401
(5.34%)
23.32M
CDTConduit Pharmaceuticals Inc
US$ 0.0811
(12.17%)
16.48M
CEROCERo Therapeutics Holdings Inc
US$ 0.0465
(9.93%)
15.72M

Discussion

View Full Feed
jimr1717 jimr1717 1 minute ago
What happened to these deal announcements?

https://www.otcmarkets.com/stock/RAKR/news/Rainmaker-Worldwide-Signs-Water-as-a-Service-Agreement-with-Jamaicas-Northern-Caribbean-University?id=265606

And this one ....

https://www.otcmarkets.com/stock/RAKR/news
RAKR
oldman69 oldman69 1 minute ago
Good to here from $5 00 bucjs and beyond. Chas you may have to change that to $19 bucks and beyond!!!
HELL YEAH!!!
IQST
La Flaca La Flaca 2 minutes ago
I understand now. I too think they would have been better off by starting that confirmatory trial, and I guarantee you that they recognize that as well. It's too late unfortunately and hopefully Europe will approve. Do you agree that if Europe approves (big IF, I know), their chances of getting FDA
AVXL
freecs freecs 2 minutes ago
Surely you can understand the difference between proactive and reactive. Pumpers are proactive. Those that come to dispel their fables are merely reactive.

If there's no pumping and fables being told, there's no need to detract and poke holes in the balloon.
RDAR
powerbattles powerbattles 3 minutes ago
$CTOR News today stated they are evaluating strategic alternatives aimed at maximizing shareholder value through potential partnerships, joint ventures, mergers, acquisitions, and licensing.
CTOR
JoJr JoJr 3 minutes ago
Are you invested in RDAR?

And if so, are you saying that RDAR is a real company like you have a real skill set?

Unlike most penny stock P & D's... ?

If that's what you're saying, welcome aboard.
RDAR
redspinelpinktopaz redspinelpinktopaz 3 minutes ago
Is there anything organic about it?
LWLG
Stock Guy777 Stock Guy777 4 minutes ago
Who would've thought that they would take the horrible Louisiana news Over the weekend as positive publicity for the stock to raise as much as it did today. 
META
harry crumb harry crumb 4 minutes ago
1.00-1.25 possile by friday, watch an learn you Ai pumping pete's! Scams belong on the pinksheets, coming soon
ILLR
flipper44 flipper44 4 minutes ago
Correct.
NWBO
freecs freecs 5 minutes ago
What's coming?
RDAR
236T568 236T568 5 minutes ago
If you ever wondered what a spineless lowlife looked like, just review this short video

https://x.com/donwinslow/status/1876363463074975767
freecs freecs 5 minutes ago
I mean, you just proved my point.
RDAR
threewheeler threewheeler 6 minutes ago
dam that sux
FDCT
Investor2014 Investor2014 6 minutes ago
I don’t think Anavex will apply to the FDA for accelerated approval because the P2b/3 trial doesn’t include any accepted surrogate endpoints and there is no confirmatory trial initiated as is now a firm requirement, but I do think they should have initiated that confirmatory trial they said they wou
AVXL
Zorax Zorax 6 minutes ago
I think roosty can still get covid if he licks the toilet seats in public bathrooms.
Number sleven Number sleven 6 minutes ago
https://www.hickenlooper.senate.gov/press_releases/hickenlooper-cotton-welch-collins-introduce-skinny-labels-big-savings-act-to-safeguard-generic-drugs-slash-drug-prices/?source=email
Sleven,
AMRN
StockItOut StockItOut 6 minutes ago
10-K: "During the year ended June 30, 2024, the Company received $0 by selling shares of common stock."

"During the year ended June 30, 2024, the Company received $2,030,000 from the issuance of convertible debt."
XERI
Flobewan Flobewan 7 minutes ago
LMAO, funny with the pieces of puzzle, I started a puzzle last week and accidentally dropped a couple of pieces, guess who found them, LOL
StockItOut StockItOut 7 minutes ago
The first ever question I posed using AI, provided a very incorrect answer.
XERI
gfp927z gfp927z 7 minutes ago
>>> Verisk Analytics, Inc. (VRSK) provides data analytics and technology solutions to the insurance markets in the United States and internationally. It offers policy language, prospective loss costs, policy writing and rating rules, and various underwriting solutions for risk selection and segmenta
VRSK
pegs1 pegs1 7 minutes ago
Test Pilot 🧑‍✈️
I want you to know why the 10q wasn’t submitted? Management needs to update investors here and now! Keeping investors in the dark isn’t the answer!……
CRTG
jimr1717 jimr1717 7 minutes ago
4 shares traded at bid to insure that the insiders receive more gifted shares with their $7,500 a month at a 30% discount to market.

Only Fools are Fooled
ATMH
GREGG THE GREEK GREGG THE GREEK 8 minutes ago
I'm looking for .10 .20 .30 and higher.

Although I did read here, recently, that " never to recover " lmfao


Amazing how many clowns exist. It's like the old VW deal in the circus...they just keep coming :-D

MONI
MONI

Your Recent History

Delayed Upgrade Clock